Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Mutant stem cells adapt their metabolism differently to outcompete normal cells in the skin.

New cancer drugs often cause skin and nail problems.

A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Tangent screens help detect visual field defects from vigabatrin.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

CXCR2 in skin cells promotes tumor growth.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

YAP and TAZ proteins are necessary for the development of two types of skin cancer.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

Upadacitinib improved multiple immune-related conditions in one patient.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Specific mutations in a receptor cause facial abnormalities and hair loss.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.